Literature DB >> 3335642

Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity.

R B Diasio1, T L Beavers, J T Carpenter.   

Abstract

Severe neurotoxicity due to 5-fluorouracil (FUra) has previously been described in a patient with familial pyrimidinemia. We now report the biochemical basis for both the pyrimidinemia and neurotoxicity in a patient we have recently studied. After administration of a "test" dose of FUra (25 mg/m2, 600 microCi[6-3H]FUra by intravenous bolus) to a patient who had previously developed neurotoxicity after FUra, a markedly prolonged elimination half-life (159 min) was observed with no evidence of FUra catabolites in plasma or cerebrospinal fluid and with 89.7% of the administered dose being excreted into the urine as unchanged FUra. Using a sensitive assay for dihydropyrimidine dehydrogenase in peripheral blood mononuclear cells, we demonstrated complete deficiency of enzyme activity in the patient and partial deficiency of enzyme activity in her father and children consistent with an autosomal recessive pattern of inheritance. Patients who are deficient in this enzyme are likely to develop severe toxicity after FUra administration.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3335642      PMCID: PMC442471          DOI: 10.1172/JCI113308

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  12 in total

1.  CEREBELLAR ATAXIA ASSOCIATED WITH FLUORINATED PYRIMIDINE THERAPY.

Authors:  C G MOERTEL; R J REITEMEIER; C F BOLTON; R G SHORTER
Journal:  Cancer Chemother Rep       Date:  1964-09

2.  THE REDUCTION OF THYMINE BY HUMAN LEUKOCYTES.

Authors:  J C MARSH; S PERRY
Journal:  Arch Biochem Biophys       Date:  1964-01       Impact factor: 4.013

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  Biochemical basis of the acute cerebellar syndrome in 5-fluorouracil chemotherapy.

Authors:  H Koenig; A Patel
Journal:  Trans Am Neurol Assoc       Date:  1969

5.  Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate.

Authors:  H Koenig; A Patel
Journal:  Arch Neurol       Date:  1970-08

6.  New defects of pyrimidine metabolism.

Authors:  S K Wadman; F A Beemer; P K de Bree; M Duran; A H van Gennip; D Ketting; F J van Sprang
Journal:  Adv Exp Med Biol       Date:  1984       Impact factor: 2.622

7.  Rapid catabolism of 5-fluorouracil in freshly isolated rat hepatocytes as analyzed by high performance liquid chromatography.

Authors:  J P Sommadossi; D A Gewirtz; R B Diasio; C Aubert; J P Cano; I D Goldman
Journal:  J Biol Chem       Date:  1982-07-25       Impact factor: 5.157

8.  Elevated urine, blood and cerebrospinal fluid levels of uracil and thymine in a child with dihydrothymine dehydrogenase deficiency.

Authors:  J A Bakkeren; R A De Abreu; R C Sengers; F J Gabreëls; J M Maas; W O Renier
Journal:  Clin Chim Acta       Date:  1984-07-31       Impact factor: 3.786

9.  Dihydropyrimidine dehydrogenase deficiency leading to thymine-uraciluria. An inborn error of pyrimidine metabolism.

Authors:  R Berger; S A Stoker-de Vries; S K Wadman; M Duran; F A Beemer; P K de Bree; J J Weits-Binnerts; T J Penders; J K van der Woude
Journal:  Clin Chim Acta       Date:  1984-08-31       Impact factor: 3.786

10.  Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile.

Authors:  G D Heggie; J P Sommadossi; D S Cross; W J Huster; R B Diasio
Journal:  Cancer Res       Date:  1987-04-15       Impact factor: 12.701

View more
  79 in total

1.  Pharmacogenetics: implementing personalized medicine.

Authors:  Enrico Mini; Stefania Nobili
Journal:  Clin Cases Miner Bone Metab       Date:  2009-01

Review 2.  Selection of extreme phenotypes: the role of clinical observation in translational research.

Authors:  José Luis Pérez-Gracia; Alfonso Gúrpide; María Gloria Ruiz-Ilundain; Carlos Alfaro Alegría; Ramon Colomer; Jesús García-Foncillas; Ignacio Melero Bermejo
Journal:  Clin Transl Oncol       Date:  2010-03       Impact factor: 3.405

3.  A new case of dihydropyrimidine dehydrogenase deficiency.

Authors:  M Brockstedt; C Jakobs; L M Smit; A H van Gennip; R Berger
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

4.  Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.

Authors:  X Wei; H L McLeod; J McMurrough; F J Gonzalez; P Fernandez-Salguero
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

Review 5.  Recent developments in the clinical pharmacology of classical cytotoxic chemotherapy.

Authors:  Alan V Boddy
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

Review 6.  Pharmacogenetics in the management of breast cancer -- prospects for individualised treatment.

Authors:  Fiona H Blackhall; Sacha Howell; Bill Newman
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375

7.  Dihydropyrimidinuria: a new inborn error of pyrimidine metabolism.

Authors:  M Duran; P Rovers; P K de Bree; C H Schreuder; H Beukenhorst; L Dorland; R Berger
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

8.  Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity.

Authors:  Steven M Offer; Natalie J Wegner; Croix Fossum; Kangsheng Wang; Robert B Diasio
Journal:  Cancer Res       Date:  2013-01-17       Impact factor: 12.701

Review 9.  Pharmacogenetics and pharmacogenomics of anticancer agents.

Authors:  R Stephanie Huang; Mark J Ratain
Journal:  CA Cancer J Clin       Date:  2009 Jan-Feb       Impact factor: 508.702

10.  Predictive Factors for Response and Toxicity in Chemotherapy: Pharmacogenomics.

Authors:  Hanna K Sanoff; Howard L McLeod
Journal:  Semin Colon Rectal Surg       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.